Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity

Journal of Neural Transmission, Supplement

Volumn , Issue 55, 1999, Pages 57-70

  Grunblatt E ^a   Mandel, S ^a   Gassen, M ^b   Youdim, M B H ^a,c,d  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b MERCK KGAA   (Germany)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d B Rappaport Fam Med Sci Building ^*  (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; APOMORPHINE; CHELATING AGENT; DEFEROXAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; IRON; OXIDOPAMINE; OXYGEN RADICAL; SCAVENGER; TYROSINE 3 MONOOXYGENASE; ANTIOXIDANT; IRON CHELATING AGENT; NEUROPROTECTIVE AGENT; NEUROTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN MITOCHONDRION; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; ENZYME INHIBITION; LIPID PEROXIDATION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; INTOXICATION; REVIEW;

ANIMALS; ANTIOXIDANTS; APOMORPHINE; FREE RADICAL SCAVENGERS; IRON CHELATING AGENTS; MICE; MPTP POISONING; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OXIDOPAMINE; RATS;

EID: 0032589184     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6369-6_6     Document Type: Article

References (54)

1. Adamson GM, Billings RE (1993) Cytokine toxicity and induction of NO synthesis activity in cultured mouse hepatocytes. Toxicol Appl Pharmacol 119: 100-107
2. Ben-Shachar D, Youdim MRH (1991) Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem 57: 2133-2135
3. Ben-Shachar D, Eshel G, Finberg JPM, Youdim MBH (1991) The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostrialal neurons. J Neurochem 56: 1441-1444
4. Braughler JM, Pregenzer JF, Chase RL, Duncan LA, Jacobson EJ, McCall JM (1987) Novel 21-aminosteroids as potent inhibitors of iron-dependent lipid peroxidation. J Biol Chem 262: 10438-10440
5. Cadet JL, Katz M, Jackson-Lewis V, Fahn S (1989) Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 476: 5-10
6. Cohen G, Werner P (1994) Free radicals oxidative stress and neurodegeneration. In: Calne DB (ed) Neurodegenerative disorders, Saunders, Philadelphia, pp 139-162
7. Colzi A, Turner K, Lee AJ (1998) Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 64: 573-576
8. Di Monte D, Dandy MS, Smith MT (1987) Increase efflux rather than oxidation is the mechanism of glutathione dspletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Biophys Res Commun 148: 153-160
9. Ebadi M, Srinivasan Sk, Baxi MD (1996) Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobiol 48: 1-19
10. Gancher S (1995) Pharmacokinetics of apomorphine in Parkinson's disease. J Neural Transm [Suppl] 45: 137-141
11. Gancher ST, Nutt JG, Woodward WR (1995) Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Disord 10: 37-43
12. Gassen M, Youdim MBH (1998) Free radical scavengers: chemical concepts and clinical relevance. J Neural Transm (In press)
13. Gassen M, Glinka Y, Pinchasi B, Youdim MBH (1996) Apomorphine is highly potent free radical scavenger in rat mitochondrial fraction. Eur J Pharmacol 308: 219-225
14. Gassen M, Gross A, Youdim MBH (1998a) Apomorphine enantiomers protect pheochromocytoma (PC12) cells from oxidative stress induced by hydrogen peroxide and 6-hydroxydopamine. Mov Disord 13: 242-248
15. 2-induced cell death. Adv Pharmacol 42: 320-324
16. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63: 793-806
17. Glinka Y, Youdim MBH (1995) Inhibition of mitochondrial complex I and IV by 6-hydroxydopamine. Euro J Pharmacol 292: 329-332
18. Glinka Y, Tipton KF, Youdim MBH (1996) Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J Neurochem 66: 2004-2010
19. Glinka Y, Gassen M, Youdim MBH (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm [Suppl] 50: 55-66
20. Greene LA, Aletta JM, Rukenstein A, Green SH (1987) PC12 pheocytoma cells, culture, nerve growth factor treatment and experimental exploitation. Methods Enzymol 147: 207-216
21. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467-469
22. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MBH (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm [PD Sect] 2: 327-340
23. Jenner P, Olanow CW (1996) Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders. In: Olanow CW, Jenner P, Youdim MBH (eds) Neurodegeneration and neuroprotection in Parkinson's disease. Academic Press, London, pp 24-45
24. Kato T, Horiuchi S, Togari A, Nagatsu T (1981) A sensitive and inexpensive high-performance liquid chromatographic assay for tyrosine hydroxylase. Experientia 37: 809-811
25. Lan J, Jiang DH (1997) Desferrioxamine and vitamin E protect aginst iron and MPTP-induced neurodegeneration in mice. J Neural Transm 104: 469-481
26. Lees AJ (1993) Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol 7: 121-128
27. LeWitt PA (1994) Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment. J Neural Transm [Suppl] 43: 171-181
28. Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MBH (1996) Dopamine, 6-hydroxydopamine, iron, and dioxygen-their mutual interactions and possible implication in the development of Parkinson's disease. Biochem Biophys Acta 1316: 160-168
29. Liu J, Mori A (1993) Monoamine metabolism provides an antioxidant defense in the brain against oxidant- and free radical-induced damage. Arch Biochem Biophys 302: 118-127
30. Matthews RT, Yang L, Beal M (1997) S-Methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity. Exp Neurol 143: 282-286
31. Mochizuki H, Imai H, Endo K, Yokomizo K, Murata Y, Hattori N, Mizuno Y (1994) Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced hemiparkinsonism in monkeys. Neurosci Lett 168: 251-253
32. Monteiro HP, Winterbourn CC (1989) 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem Pharmacol 38: 4177-4182
33. O'Carroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF (1983) The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 322: 198-202
34. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 660: 8-18
35. Olanow CW (1993) A scientific rationale for protective therapy in Parkinson's disease. J Neural Transm [Gen. Sect] 91: 161-180
36. Olanow CW, Youdim MBH (1996) Iron and neurodegeneration: Prospects for neuroprotection. In: Olanow CW, Jenner P, Youdim MBH (eds) Neurodegeneration and neuroprotection in Parkinson's disease. Academic Press, New York, pp 50-67
37. Perumal AS, Gopal VB, Tordzro WK, Cooper TB, Cadet JL (1992) Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 29: 699-701
38. Przuntek H (1994) Clinical aspects of neuroprotection in Parkinson's disease. J Neural Transm [Suppl] 43: 163-169
39. Rogers JT, Bridges KR, Durmowicz GP, Glass J, Zuron PE, Munro HN (1990) Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem 265: 14572-14578
40. Sam EE, Verbeke N (1995) Free radical scavenging properties of apomorphine enantiomers and dopamine - possible implication in their mechanism of action in parkinsonism. J Neural Transm [PD Sect] 10: 115-127
41. Sam E, Jeanjean AP, Maloteaux JM, Verbeke N (1995) Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. Eur J Drug Metab Parmacokinet 20: 27-33
42. + toxicity on striatal dopaminergic terminals. J Neurochem 68: 732-738
43. Seiser C, Teixeira S, Kuhn LC (1993) Interleukin-2 dependent transcriptional and post-transcriptional regulation of transferrin receptor mRNA, J Biol Chem 268: 13074-13080
44. Sengstock GJ, Olanow CW, Dunn AJ, Barone S Jr, Arendash GW (1994) Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra. Exp Neurol 130: 82-94
45. Simeonova PP, Luster MI (1995) Iron and reactive oxygen species in the asbestos-induced tumor necrosis factor-alpha response from alveolar macrophages. Am J Respir Cell Mol Biol 12: 676-683
46. Singer TP, Castagnoli N Jr, Ramsay RR, Treor AJ (1987) Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 49: 1-8
47. Sorrenti V, Di Giacomo C, Renis M, Russo A, La Delfa C, Perez-Polo JR, Vanclla A (1994) Lipid peroxidation and survival in rats following cerebral post-ischemic reperfusion: effect of drugs with different molecular mechanisms. Drugs Exp Clin Res 20: 185-189
48. Stadtman ER (1993) Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu Rev Biochem 62: 797-821
49. Temlett JA, landsberg JP, Watt F, Grime GW (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian african green monkey: evidence from proton microprobe clement microanalysis. J Neurochem 62: 134-146
50. Vimard F, Nouvelot A, Duval D (1996) Cytotoxic effects of oxidative stress on neuronallike pheochromocytoma cells. Biochem Pharmacol 51: 1389-1395
51. Youdim MBH, Ben-Shachar D, Riederer P (1990) The role of monoamine oxidase, ironmelanin interaction, and intracellular calcium in Parkinson's disease. J Neural Transm [Suppl] 32: 239-248
52. Youdim MBH, Ben-Shachar D, Riederer P (1993) The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord 8: 1-12
53. Zhao W, Richardson JS, Mombourquette MJ, Weil JA (1995) An in vitro EPR study of the free-radical scavenging action of the lazaroid antioxidants U-74500A and U-78517F. Free Radie Biol Med 19: 21-30
54. Zigmond MJ, Berger TW, Grace AA, Stricker EM (1989) Compensatory responses to nigrostriatal bundle injury. Mol Chem Neuropathol 10: 185-200